These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10433563)

  • 1. Human immunodeficiency virus infection, anemia, and survival.
    Moore RD
    Clin Infect Dis; 1999 Jul; 29(1):44-9. PubMed ID: 10433563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity.
    Moyle G
    AIDS Rev; 2002; 4(1):13-20. PubMed ID: 11998779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin for HIV-related anemia.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1998 Oct; 4(10):18-24. PubMed ID: 11365957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin in anemia of prematurity.
    Whitehall JS; Patole SK; Campbell P
    Indian Pediatr; 1999 Jan; 36(1):17-27. PubMed ID: 10709119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus.
    Buskin SE; Sullivan PS
    Transfusion; 2004 Jun; 44(6):826-32. PubMed ID: 15157246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer.
    Henry DH
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):12-6. PubMed ID: 8153671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma].
    Spicka I; Haber J; Petruzelka L; Kolesková E; Sálková J; Straub J; Zounar R; Klener P
    Cas Lek Cesk; 1996 Jul; 135(14):450-3. PubMed ID: 8925545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythropoietin treatment of anemia associated with human immunodeficiency virus infection].
    Moreno García M
    Med Clin (Barc); 1997 Feb; 108(7):266-71. PubMed ID: 9121196
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin.
    Barlogie B
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):25-7. PubMed ID: 8153675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.
    Henry DH; Beall GN; Benson CA; Carey J; Cone LA; Eron LJ; Fiala M; Fischl MA; Gabin SJ; Gottlieb MS
    Ann Intern Med; 1992 Nov; 117(9):739-48. PubMed ID: 1416576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of anemia, treatments for anemia, and survival in patients with human immunodeficiency virus infection.
    Sullivan P
    J Infect Dis; 2002 May; 185 Suppl 2():S138-42. PubMed ID: 12001035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children.
    Allen UD; Kirby MA; Goeree R
    Pediatr AIDS HIV Infect; 1997 Feb; 8(1):4-11. PubMed ID: 11361510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternatives to blood product transfusion in the critically ill: erythropoietin.
    Stubbs JR
    Crit Care Med; 2006 May; 34(5 Suppl):S160-9. PubMed ID: 16617261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.
    Rosenzweig MQ; Bender CM; Lucke JP; Yasko JM; Brufsky AM
    J Pain Symptom Manage; 2004 Feb; 27(2):185-90. PubMed ID: 15157043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of anemia, differential diagnosis, and treatment options in human immunodeficiency virus infection.
    Claster S
    J Infect Dis; 2002 May; 185 Suppl 2():S105-9. PubMed ID: 12001030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical use of erythropoietin].
    Franchini M; Gandini G; Lippi G; De Gironcoli M; Cantini M; Aprili G
    Recenti Prog Med; 2004 Mar; 95(3):129-36; quiz 185. PubMed ID: 15143948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia in the setting of cancer and human immunodeficiency virus.
    Levine AM
    Clin Infect Dis; 2003; 37 Suppl 4():S304-14. PubMed ID: 14581999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.